rituximab,ibrutinib,bendamustine
biogen,roche,teva pharmaceuticals,janssen,abbvie
['lymphoma', 'ibru', 'mantle,(-dismantle)', 'rituximab', 'bendamustine']
oncology news update: 'eha 2022: ibrutinib combination with bendamustine-rituximab and rituximab maintenance as a first-line treatment for older patients with mantle cell lymphoma significantly improves pfs' has been published on oncology ... - #oncnews 
Creating Innovative Resources for the Australian Oncology Community and Beyond. Home of The Oncology Newsletter, The Oncology Podcast and https://t.co/xBVIOdvL7D